$171.75
0.250.15%
Dernière mise à jour: 11:45 AM
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Charles River Laboratories International Inc a un objectif de cours consensuel de $201.12 basé sur les évaluations de 21 analystes. Le plus élevé est $275, publié par Wells Fargo le septembre 22, 2023. Le plus bas est $165, publié par JP Morgan le novembre 6, 2025. Les 3 évaluations d’analystes les plus récentes ont été publiées par Morgan Stanley, TD Cowen et JP Morgan le novembre 11, 2025, novembre 10, 2025 et novembre 6, 2025, respectivement. Avec un objectif de cours moyen de $182.33 entre Morgan Stanley, TD Cowen et JP Morgan, il existe une variation implicite de 6.16% upside pour Charles River Laboratories International Inc selon ces dernières évaluations d’analystes.
Sociétés d'analyse émettant des recommandations1
Morgan Stanley
TD Cowen
JP Morgan
Barclays
Baird
1calculé à partir des notes des analystes
Notes d'analystes pour Charles River
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/11/2025 | 7.71% | Morgan Stanley | $170 → $185 | Maintains | Equal-Weight | |||
11/10/2025 | 14.7% | TD Cowen | $205 → $197 | Maintains | Buy | |||
11/06/2025 | -3.93% | JP Morgan | $160 → $165 | Maintains | Neutral | |||
11/06/2025 | 22.27% | Barclays | $195 → $210 | Maintains | Overweight | |||
11/06/2025 | 15.87% | Baird | $178 → $199 | Upgrade | Neutral → Outperform | |||
10/17/2025 | 1.31% | Mizuho | $155 → $174 | Maintains | Neutral | |||
10/06/2025 | — | William Blair | — | Upgrade | Market Perform → Outperform | |||
10/03/2025 | 16.45% | Evercore ISI Group | $190 → $200 | Maintains | Outperform | |||
10/02/2025 | 13.54% | Barclays | $165 → $195 | Upgrade | Equal-Weight → Overweight | |||
09/09/2025 | 13.54% | Jefferies | $142 → $195 | Upgrade | Hold → Buy | |||
08/08/2025 | 10.63% | Evercore ISI Group | $180 → $190 | Maintains | Outperform | |||
08/07/2025 | -6.84% | JP Morgan | $145 → $160 | Maintains | Neutral | |||
08/07/2025 | -3.93% | Barclays | $155 → $165 | Maintains | Equal-Weight | |||
07/09/2025 | 4.8% | Evercore ISI Group | $170 → $180 | Maintains | Outperform | |||
07/09/2025 | 16.45% | Citigroup | $150 → $200 | Upgrade | Neutral → Buy | |||
05/23/2025 | 5.97% | Redburn Atlantic | $188 → $182 | Upgrade | Neutral → Buy | |||
05/08/2025 | -9.75% | Barclays | $145 → $155 | Maintains | Equal-Weight | |||
05/08/2025 | -18.49% | Baird | $118 → $140 | Maintains | Neutral | |||
04/10/2025 | -15.57% | Barclays | $160 → $145 | Maintains | Equal-Weight | |||
04/09/2025 | -9.75% | Mizuho | $175 → $155 | Maintains | Neutral | |||
03/21/2025 | -1.02% | Goldman Sachs | $190 → $170 | Downgrade | Buy → Neutral | |||
03/04/2025 | 1.89% | Citigroup | $155 → $175 | Upgrade | Sell → Neutral | |||
03/03/2025 | 9.46% | Redburn Atlantic | $171 → $188 | Upgrade | Sell → Neutral | |||
02/20/2025 | -3.93% | JP Morgan | $175 → $165 | Maintains | Neutral | |||
02/20/2025 | 0.73% | Baird | $177 → $173 | Maintains | Neutral | |||
02/20/2025 | -6.84% | Barclays | $166 → $160 | Maintains | Equal-Weight | |||
02/18/2025 | -3.35% | Barclays | $205 → $166 | Maintains | Equal-Weight | |||
02/05/2025 | 7.13% | Morgan Stanley | $220 → $184 | Maintains | Equal-Weight | |||
02/03/2025 | 1.89% | JP Morgan | $215 → $175 | Maintains | Neutral | |||
01/23/2025 | 10.63% | Goldman Sachs | $220 → $190 | Maintains | Buy | |||
01/22/2025 | — | William Blair | — | Downgrade | Outperform → Market Perform | |||
01/17/2025 | 7.71% | UBS | $250 → $185 | Downgrade | Buy → Neutral | |||
01/14/2025 | — | William Blair | — | Reiterates | Outperform → Outperform | |||
12/16/2024 | 28.09% | Morgan Stanley | $225 → $220 | Maintains | Equal-Weight | |||
12/13/2024 | 22.27% | B of A Securities | $220 → $210 | Maintains | Neutral | |||
11/11/2024 | 32.17% | TD Cowen | $203 → $227 | Maintains | Hold | |||
11/07/2024 | 45.56% | UBS | $240 → $250 | Maintains | Buy | |||
11/07/2024 | 31% | Evercore ISI Group | $190 → $225 | Maintains | In-Line | |||
10/23/2024 | -2.77% | CLSA | — | → $167 | Initiates | → Underperform | ||
10/16/2024 | 19.36% | Barclays | $210 → $205 | Maintains | Equal-Weight | |||
10/14/2024 | -12.08% | Redburn Atlantic | → $151 | Initiates | → Sell | |||
10/07/2024 | 10.63% | Evercore ISI Group | $225 → $190 | Downgrade | Outperform → In-Line | |||
10/02/2024 | 25.18% | B of A Securities | $250 → $215 | Downgrade | Buy → Neutral | |||
10/01/2024 | 1.89% | Citigroup | $215 → $175 | Downgrade | Neutral → Sell | |||
09/20/2024 | 10.63% | Baird | $191 → $190 | Maintains | Neutral | |||
08/12/2024 | 18.2% | TD Cowen | $228 → $203 | Maintains | Hold | |||
08/08/2024 | 25.18% | Morgan Stanley | $235 → $215 | Maintains | Equal-Weight | |||
08/08/2024 | 22.27% | Barclays | $230 → $210 | Maintains | Equal-Weight | |||
08/08/2024 | 39.74% | UBS | $290 → $240 | Maintains | Buy | |||
08/08/2024 | 31% | Evercore ISI Group | $265 → $225 | Maintains | Outperform | |||
08/08/2024 | 45.56% | Goldman Sachs | $290 → $250 | Maintains | Buy | |||
08/08/2024 | 19.36% | JP Morgan | $270 → $205 | Downgrade | Overweight → Neutral | |||
08/08/2024 | 11.21% | Baird | $239 → $191 | Downgrade | Outperform → Neutral | |||
07/10/2024 | 39.16% | Baird | $271 → $239 | Maintains | Outperform | |||
06/28/2024 | 33.92% | Barclays | → $230 | Initiates | → Equal-Weight | |||
06/28/2024 | — | Argus Research | — | Downgrade | Buy → Hold | |||
06/07/2024 | 36.83% | Mizuho | → $235 | Initiates | → Neutral | |||
06/06/2024 | 68.85% | Goldman Sachs | → $290 | Initiates | → Buy | |||
05/13/2024 | 32.75% | TD Cowen | $260 → $228 | Maintains | Hold | |||
05/10/2024 | 57.21% | Baird | $282 → $270 | Maintains | Outperform | |||
03/18/2024 | 68.85% | Argus Research | $240 → $290 | Maintains | Buy | |||
02/15/2024 | 63.03% | JP Morgan | $270 → $280 | Maintains | Overweight | |||
02/15/2024 | 54.29% | Evercore ISI Group | $260 → $265 | Maintains | Outperform | |||
02/15/2024 | 68.85% | UBS | $270 → $290 | Maintains | Buy | |||
02/15/2024 | 45.56% | Citigroup | $215 → $250 | Maintains | Neutral | |||
02/15/2024 | 56.04% | Baird | $252 → $268 | Maintains | Outperform | |||
02/15/2024 | — | Guggenheim | — | Downgrade | Buy → Neutral | |||
12/20/2023 | 57.21% | JP Morgan | $210 → $270 | Maintains | Overweight | |||
12/11/2023 | 25.18% | Citigroup | $190 → $215 | Maintains | Neutral | |||
11/10/2023 | 19.36% | Morgan Stanley | $220 → $205 | Maintains | Equal-Weight | |||
11/09/2023 | 25.18% | UBS | $250 → $215 | Maintains | Buy | |||
10/24/2023 | 28.09% | Morgan Stanley | $235 → $220 | Maintains | Equal-Weight | |||
09/25/2023 | 21.69% | TD Cowen | $212 → $209 | Maintains | Market Perform | |||
09/22/2023 | 49.05% | Baird | $267 → $256 | Maintains | Outperform | |||
09/22/2023 | 31% | Guggenheim | $255 → $225 | Maintains | Buy | |||
09/22/2023 | 60.12% | Wells Fargo | $280 → $275 | Maintains | Overweight | |||
09/13/2023 | 23.44% | TD Cowen | → $212 | Initiates | → Market Perform | |||
08/10/2023 | 45.56% | JP Morgan | $225 → $250 | Maintains | Overweight | |||
08/10/2023 | 42.65% | B of A Securities | $235 → $245 | Maintains | Buy | |||
07/11/2023 | 31% | Citigroup | $260 → $225 | Downgrade | Buy → Neutral | |||
07/10/2023 | 31% | Citigroup | $260 → $225 | Downgrade | Buy → Neutral | |||
05/15/2023 | 31% | Morgan Stanley | $230 → $225 | Maintains | Equal-Weight | |||
05/12/2023 | 48.47% | Credit Suisse | $260 → $255 | Maintains | Outperform | |||
05/12/2023 | 63.03% | Wells Fargo | $290 → $280 | Maintains | Overweight | |||
03/28/2023 | 18.2% | Jefferies | $233 → $203 | Maintains | Hold | |||
02/23/2023 | 51.38% | Credit Suisse | $280 → $260 | Maintains | Outperform | |||
02/23/2023 | 33.92% | Morgan Stanley | $241 → $230 | Maintains | Equal-Weight | |||
02/23/2023 | 51.38% | Citigroup | $280 → $260 | Maintains | Buy | |||
02/23/2023 | 48.47% | Guggenheim | → $255 | Upgrade | Neutral → Buy | |||
01/12/2023 | — | Jefferies | — | Downgrade | Buy → Hold | |||
01/11/2023 | 65.94% | Baird | $275 → $285 | Maintains | Outperform |
FAQ
Quel est le cours indicatif de l'action Charles River (CRL) ?
Le dernier objectif de prix pour Charles River (NYSE:CRL) a été rapporté par Morgan Stanley le novembre 11, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $185.00 s'attendant à ce que CRL se rise dans les 12 prochains mois (un possible changement de 7.71% upside). 35 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Charles River (CRL) ?
La dernière note d'analyste pour Charles River (NYSE:CRL) a été fournie par Morgan Stanley, et Charles River maintenu leur note equal-weight.
Quand a eu lieu la dernière mise à niveau pour Charles River (CRL) ?
La dernière amélioration pour Charles River Laboratories International Inc a eu lieu le novembre 6, 2025 lorsque Baird a augmenté leur objectif de prix à $199. Baird avait précédemment a neutral pour Charles River Laboratories International Inc.
Quand a eu lieu la dernière dégradation pour Charles River (CRL) ?
La dernière réduction pour Charles River Laboratories International Inc a eu lieu le mars 21, 2025 lorsque Goldman Sachs a changé leur objectif de prix de $190 à $170 pour Charles River Laboratories International Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Charles River (CRL) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Charles River, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Charles River a été déposée le novembre 11, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers novembre 11, 2026.
La note d'analyste pour Charles River (CRL) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Charles River (CRL) était un maintenu avec un objectif de prix de $170.00 à $185.00. Le prix actuel de Charles River (CRL) est de $171.75, ce qui est within la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.